Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
Fulgent Reports First Quarter 2026 Financial Results
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of “Hold” by Analysts
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
Fulgent Genetics, Inc. (NASDAQ:FLGT) Sees Large Increase in Short Interest
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Fulgent Genetics: A Major Market Misconception
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of “Hold” by Brokerages
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Fulgent Genetics Q4 Earnings Call Highlights
Fulgent Genetics, Inc. (FLGT) Q4 2025 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q4 Earnings Top Estimates
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
Fulgent Genetics (NASDAQ:FLGT) & PPJ Enterprise (OTCMKTS:PPJE) Head to Head Survey
Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock
SG Americas Securities LLC Purchases New Position in Fulgent Genetics, Inc. $FLGT
Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Average Rating of “Moderate Buy” from Analysts
New Strong Buy Stocks for January 12th
Contrasting Bullfrog AI (NASDAQ:BFRG) & Fulgent Genetics (NASDAQ:FLGT)
Analyzing Careview Communications (OTCMKTS:CRVW) & Fulgent Genetics (NASDAQ:FLGT)
FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
Financial Contrast: Patient Portal Technologies (OTCMKTS:PPRG) versus Fulgent Genetics (NASDAQ:FLGT)
Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript
Fulgent to Participate in Upcoming Conferences
Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
Fulgent Reports Third Quarter 2025 Financial Results
Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference
Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025
Fulgent Genetics: A Risky Bet or a Hidden Gem?
Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)
Fulgent (FLGT) Q2 Revenue Jumps 16%